Suggestions
Don Lazas MD
Co-Founder & CMO at ObjectiveHealth
Don Lazas MD is a distinguished physician leader with over two decades of experience in caring for patients and managing healthcare systems. He is an expert in digestive diseases, clinical research, and innovation in the medical field.
Dr. Lazas is the owner and operator of Associates in Gastroenterology, PLC, a prominent specialty practice in Nashville, as well as Associated Endoscopy, LLC, a state-of-the-art surgery center.
Beyond his medical practice, he is actively involved in investing and consulting in medical technology businesses, with a keen focus on leveraging technology to enhance the physician-patient relationship.
He is the Founder and Managing Partner of NueCura Partners, LLC, a leading angel investment company in Nashville, driving innovation in healthcare and beyond.
Dr. Lazas holds a Doctor of Medicine degree from The George Washington University School of Medicine and has received post-graduate training at Walter Reed Army Medical Center. He is recognized as a Fellow of the American College of Physicians and the American Gastroenterological Association.
His professional journey includes serving as a Major in the Army Medical Corps, reflecting his commitment to both medical excellence and military service.
Dr. Lazas has been associated with various organizations and initiatives, including co-founding ObjectiveHealth and Digestive Health Research. He has held key positions at EvidenceCare, NueCura Partners, LLC, and several other prestigious organizations, showcasing his diverse expertise and leadership in the medical and entrepreneurial realms.
Highlights
Patients with diabetes are at substantially increased risk for advanced liver disease and liver cancer related to fatty liver disease. All diabetics should be assessed with elastography and / or next generation blood based biomarkers. New society guidelines support this approach.
Annual costs for NASH + Type 2 DM estimated in this study to be $16,000 per patient per year. At ObjectiveHealth research we are seeing a $16,000 per patient per year offset in HC cost. Therapeutics, advanced diagnostics, education, coaching in our community-based physician partnerships. Research is another payer in the arc of HC and an important care ancillary in these complex patient populations.
